CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Quark Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Quark Pharmaceuticals, Inc.
6501 Dumbarton Circle
Phone: (510) 402-4020p:510 402-4020 Fremont, CA  94555  United States Ticker: QURKQURK
Quark Pharmaceuticals, Inc. filed a Registration Withdrawal Request of its Form S-1 (File No. 333-169584) with the SEC on 9/26/2011. The Company has decided not to proceed with the offering covered by the Form at this time.
This is a Subsidiary, click here for the Parent Company
Business Summary
Quark Pharmaceuticals, Inc. is one of the world leaders in discovery and development of novel siRNA therapeutics. Such therapeutics act via engaging a natural mechanism of inhibition of target gene expression, RNA interference (RNAi). The Company’s fully integrated drug discovery and development platform spans from therapeutic target identification to drug development. In addition to QPI-1002, Quark has clinical development programs in several ophthalmology indications as well as a rich pre-clinical pipeline. The Company is headquartered in Fremont, CA and operates a research facility in Ness-Ziona, Israel.
(Source: PRESS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201012/31/2010YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman and Chief Executive Officer DanielZurr
Chief Financial Officer TomerNatan
Chief Operating Officer RamiSkaliter
3 additional Officers and Directors records available in full report.

Business Names
Business Name
QBI Enterprises, Ltd.
Quark Metabolix Inc.
QURK

General Information
Federal Tax Id: 943192416
Fax Number: (510) 402-4021
Email Address: qbi@quarkpharma.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023